STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
BALANCE at Sep. 30, 2016	$ 62,480	$ 284,649,429	$ (285,391,122)	$ (679,213)
BALANCE, Shares at Sep. 30, 2016	6,248,035
Sale of common stock	$ 47,389	10,482,917		10,530,306
Sale of common stock, Shares	4,738,920
Issuance of warrants in connection with sale of common stock		(4,665,683)		(4,665,683)
Warrants issued with notes payable		1,108,867		1,108,867
Beneficial conversion feature on notes payable		1,108,867		1,108,867
401(k) contributions paid in common stock	$ 799	150,509		151,308
401(k) contributions paid in common stock, Shares	79,941
Conversion of notes payable to common stock	$ 2,667	448,033		450,700
Conversion of notes payable to common stock, Shares	266,686
Stock issued to nonemployees for service	$ 766	203,817		204,583
Stock issued to nonemployees for service, Shares	76,551
Shares issued for settlement of clinical research costs	$ 4,800	1,305,600		1,310,400
Shares issued for settlement of clinical research costs, shares	480,000
Equity based compensation - employees	$ 130	1,481,120		1,481,250
Equity based compensation - employees, Shares	13,000
Equity based compensation - non-employees		24,925		24,925
Net loss			(14,363,287)	(14,363,287)
BALANCE at Sep. 30, 2017	$ 119,031	296,298,401	(299,754,409)	(3,336,977)
BALANCE, Shares at Sep. 30, 2017	11,903,133
Sale of common stock	$ 76,906	11,508,752		11,585,658
Sale of common stock, Shares	7,690,623
Warrant exercises	$ 40,721	10,752,142		10,792,863
Warrant exercises, shares	4,072,109
Warrants issued with notes payable		947,616		947,616
401(k) contributions paid in common stock	$ 937	144,153		145,090
401(k) contributions paid in common stock, Shares	93,640
Conversion of notes payable to common stock	$ 11,950	2,363,066		2,375,016
Conversion of notes payable to common stock, Shares	1,194,930
Stock issued to nonemployees for service	$ 3,562	689,626		693,188
Stock issued to nonemployees for service, Shares	356,197
Shares issued for settlement of clinical research costs	$ 22,600	5,484,800		5,507,400
Shares issued for settlement of clinical research costs, shares	2,260,000
Equity based compensation - employees		2,743,267		2,743,267
Employee stock purchases	$ 4,639	380,361		385,000
Employee stock purchases, shares	463,855
Net loss			(31,837,205)	(31,837,205)
BALANCE at Sep. 30, 2018	$ 280,346	$ 331,312,184	$ (331,591,614)	$ 916
BALANCE, Shares at Sep. 30, 2018	28,034,487